Pluristem Therapeutics, Inc. (PSTI) and NYU Medical Center Partner in Study of Diabetic Foot Ulcers

By @ibtimes on

Today, Pluristem Therapeutics, Inc. and New York University Medical Center jointly announced that they have formed a partnership to study the use of Pluristem’s proprietary placenta-derived PLX cells for the treatment of Diabetic Foot Ulcers (DFU). The pre-clinical studies are the first step towards a potential Phase II clinical study for treatment of DFU.

An in vitro and a series of animal models will be used to evaluate the role PLX cells have in healing DFU. Through a novel academic-industrial collaborative research paradigm, these trials, with proposed support from the National Institutes of Health (NIH), will be used as a bridge towards the potential treatment of patients with diabetic foot ulcers.

The principal investigator will be Weiliam Chen, R.Ph. Ph.D., Director of the Tissue Engineering Research Laboratory, Department of Surgery at NYU’s Helen L. and Martin S. Kimmel Wound Healing Center. Dr. Chen commented, “Diabetes affects over 170 million people worldwide and more than 20 million Americans with the prevalence expected to double by 2030. Chronic diabetic foot ulcers are the leading cause of lower extremity amputations,” said Dr. Chen. “No new therapy for diabetic chronic wounds has been introduced into clinical use since 1998 and there is a critical unmet need for innovative therapies able to accelerate DFU healing, prevent amputation and reduce associated morbidity and mortality.”

“This partnership with Pluristem is important to developing an innovative advanced cellular therapy,” added Dr. Chen. “Many diabetic patients have advanced atherosclerosis and have lower extremity vascular insufficiencies. Pluristem’s PLX cells can stimulate angiogenesis, which is highly advantageous in treating diabetic chronic wounds. Besides, the PLX cells can directly address cellular impairment in diabetic wounds leading to tissue regeneration in the wound beds.”

“We are very proud to be working with a world-renowned expert such as Dr. Chen and partnering with the NYU Medical Center in using PLX cells for the potential treatment of Diabetic Foot Ulcers,” said Zami Aberman, Chairman and Chief Executive Officer of Pluristem. “Our PLX-PAD cells have been shown to be safe and potentially effective and to improve the quality of life in patients with Peripheral Artery Disease (PAD), some of whom had suffered from ulcers. We are, therefore, excited about testing the PLX cells’ effectiveness in treating DFU.”

Join the Discussion